Literature DB >> 2460637

Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

H W Virgin1, R Bassel-Duby, B N Fields, K L Tyler.   

Abstract

The mammalian reoviruses have provided a valuable model for studying the pathogenesis of viral infections of the central nervous system (CNS). We have used this model to study the effect of antibody on disease produced by the neurally spreading reovirus type 3 (Dearing) (T3). Polyclonal and monoclonal antibodies protect mice from fatal infection with T3 after either footpad or intracerebral virus challenge. Protection occurs with monoclonal antibodies directed against the viral cell attachment protein sigma 1, and with polyclonal antisera without T3 sigma 1 binding activity. In vivo protection occurs with both neutralizing and nonneutralizing monoclonal antibodies. Antibody-mediated protection does not require serum complement and, under specific circumstances, can occur via Fc-independent mechanisms. Antibody can protect mice when transferred up to 5 days after intracerebral challenge and up to 7 days after footpad challenge, times when high titers of virus are present in the CNS. Thus, antibody mediated protection against this neurally spreading virus does not require neutralizing antibody or serum complement and occurs even in the face of established CNS infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460637      PMCID: PMC253571     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

2.  The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells.

Authors:  A Miller; H C Morse; J Winkelstein; N Nathanson
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

3.  Sigma 1 protein of mammalian reoviruses extends from the surfaces of viral particles.

Authors:  D B Furlong; M L Nibert; B N Fields
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

5.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

6.  Reovirus type 3 encephalitis: observations of virus-cell interactions in neural tissues. II. Electron microscopic studies.

Authors:  N K Gonatas; G Margolis; L Kilham
Journal:  Lab Invest       Date:  1971-02       Impact factor: 5.662

7.  Immune complex effects on murine macrophages. I. Immune complexes suppress interferon-gamma induction of Ia expression.

Authors:  H W Virgin; G F Wittenberg; E R Unanue
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

8.  Evidence for functional domains on the reovirus type 3 hemagglutinin.

Authors:  S J Burstin; D R Spriggs; B N Fields
Journal:  Virology       Date:  1982-02       Impact factor: 3.616

9.  Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation.

Authors:  R S Fujinami; M B Oldstone
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

10.  Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies.

Authors:  J H Mathews; J T Roehrig; D W Trent
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  168 in total

1.  Complete in vitro assembly of the reovirus outer capsid produces highly infectious particles suitable for genetic studies of the receptor-binding protein.

Authors:  K Chandran; X Zhang; N H Olson; S B Walker; J D Chappell; T S Dermody; T S Baker; M L Nibert
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein sigma3.

Authors:  Judit Jané-Valbuena; Laura A Breun; Leslie A Schiff; Max L Nibert
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Postinfection treatment with antiviral serum results in survival of neural cells productively infected with virulent poliovirus.

Authors:  E A Tolskaya; T A Ivannikova; M S Kolesnikova; S G Drozdov; V I Agol
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  A single mutation in the carboxy terminus of reovirus outer-capsid protein sigma 3 confers enhanced kinetics of sigma 3 proteolysis, resistance to inhibitors of viral disassembly, and alterations in sigma 3 structure.

Authors:  Gregory J Wilson; Emma L Nason; Charles S Hardy; Daniel H Ebert; J Denise Wetzel; B V Venkataram Prasad; Terence S Dermody
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Transport to late endosomes is required for efficient reovirus infection.

Authors:  Bernardo A Mainou; Terence S Dermody
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

6.  A post-entry step in the mammalian orthoreovirus replication cycle is a determinant of cell tropism.

Authors:  Laura S Ooms; Takeshi Kobayashi; Terence S Dermody; James D Chappell
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

7.  Identification of the viral genes responsible for growth of strains of reovirus in cultured mouse heart cells.

Authors:  Y Matoba; B Sherry; B N Fields; T W Smith
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

8.  Derivation and characterization of an efficiently myocarditic reovirus variant.

Authors:  B Sherry; F J Schoen; E Wenske; B N Fields
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

9.  Utilization of sialylated glycans as coreceptors enhances the neurovirulence of serotype 3 reovirus.

Authors:  Johnna M Frierson; Andrea J Pruijssers; Jennifer L Konopka; Dirk M Reiter; Ty W Abel; Thilo Stehle; Terence S Dermody
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Identification of functional domains in reovirus replication proteins muNS and mu2.

Authors:  Takeshi Kobayashi; Laura S Ooms; James D Chappell; Terence S Dermody
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.